Intrinsiqq

Meds Apotek AB (MEDS.XSTO) Quality Score

MEDS.XSTO
Quality52

Valuation is the primary weakness (avg 50/100). No single area scores well.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
60/100
28.8x

25–30x, paying a growth premium

Cash Flow Multiple
40/100
570.5x

Above 30x, cash flow yield is thin

Revenue Growth
100/100
18.1%

Above 10% CAGR, strong compounder

Cash Flow Growth
0/100
-75.9%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
0/100
10.9%

Heavy dilution above 5%

Margin Trend
100/100
+8.0pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-kr 38M

Net cash position, no leverage concern

2023
kr 51M
kr 65M
2024
kr 21M
kr 24M
2025
kr 45M
kr 7M
Return on Capital
0/100
-1.8%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Meds Apotek AB (MEDS.XSTO) quality: score, margins and returns

Meds Apotek AB (MEDS.XSTO) scores 52/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 0.4% operating margins and -1.8% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Meds Apotek AB (MEDS.XSTO) a high-quality business?+

Meds Apotek AB scores 52 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 0.4% operating margin and a -1.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Meds Apotek AB's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from MEDS.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Meds Apotek AB scores well and where it falls behind.

What is Meds Apotek AB's return on invested capital (ROIC)?+

Meds Apotek AB earns about -1.8% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to MEDS.XSTO's margins and growth on this scorecard to judge durability.

How profitable is Meds Apotek AB?+

Meds Apotek AB runs an operating margin of about 0.4% and a net margin of about 1.4%. Revenue has grown at roughly 23.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on MEDS.XSTO: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Internet Retail

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.